atezolizumab
roche
['immotion010', 'rcc,(-irccs),(-srcc),(-urcc)', 'improve ', 'renal,(-adrenal)', 'atezo']
immotion010 phase 3 trial results showed that adjuvant treatment with atezolizumab does not improve the outcomes of individuals with renal cell carcinoma (rcc) at increased risk for recurrence after nephrectomy. #drugdevelopment #oncology #esmo2022 
Early Drug Development Group is a CRO specialized in the preclinical and early clinical development of novel leads in oncology.